Peptidream Inc. (JP:4587)
:4587
Want to see JP:4587 full AI Analyst Report?
4587 Stock Chart & Stats
¥1669.00
-¥31.00(-1.24%)
At close: 4:00 PM EST
¥1669.00
-¥31.00(-1.24%)
Day’s Range― - ―
52-Week Range¥1,058.50 - ¥1,824.00
Previous CloseN/A
Volume553.80K
Average Volume (3M)1.01M
Market Cap
¥142.74B
Enterprise Value¥135.60B
Total Cash (Recent Filing)¥25.55B
Total Debt (Recent Filing)¥16.34B
Price to Earnings (P/E)―
Beta0.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding130,010,400
10 Day Avg. Volume808,920
30 Day Avg. Volume1,013,253
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,562.50Price Target Upside53.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformPeptiDream’s PDPS is a durable competitive asset that underpins repeated discovery collaborations and enables differentiated modalities (macrocyclic peptides, PDCs). Proven scientific wins (large-animal and in vivo POCs) raise barriers to entry and support recurring R&D revenues and licensing opportunities over the medium term.
Advancing Clinical PipelineRapid conversion of discovery programs into clinical-stage assets diversifies binary risk and increases the cadence of milestone catalysts. A larger, balanced portfolio across radiopharma and non-RI projects improves partner appeal and the chance of multiple near-to-midterm value inflection points, supporting durable upside.
Net-Cash Position & Manageable LeverageA JPY 28.6B cash stockpile and modest debt (debt/equity ~0.33) give the company runway to fund higher R&D, clinical programs and phased manufacturing buildouts without immediate financing. This balance-sheet strength reduces refinancing risk and supports execution of multi-year development plans.
Bears Say
Negative Cash GenerationTTM operating and free cash flow turning meaningfully negative signals a reversal from prior cash generation. If milestone/upfront receipts are delayed, sustained cash burn will pressure liquidity planning, may force financing or cutbacks, and constrains ability to fund expanded R&D and manufacturing programs.
Revenue Timing & Partner DependenceBusiness model relies heavily on discrete partner deals and large upfronts. Delays or missed out-licensing (e.g., oral myostatin) create material revenue volatility, make near-term profitability contingent on partner timing, and heighten execution risk given limited visibility into counterparties and deal economics.
Rising Costs & Capex Timing RiskHigher R&D budgets and rising headcount materially increase fixed operating burn while key manufacturing capacity and HQ projects are delayed into 2027–2028. This combination raises the break-even burden and extends the time before internal production and revenue uplift materialize, stressing finances if deals slip.
Peptidream News
4587 FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was ¥1058.50 and its highest was ¥1824.00 in the past 12 months.
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is ¥142.74B.
When is Peptidream Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Peptidream Inc.’s earnings last quarter?
Currently, no data Available
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in JP:4587
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
4587 Company Deck
4587 Earnings Call
Q4 2026
0:00 / 0:00
4587 Stock 12 Month Forecast
Average Price Target
¥2,562.50
▲(53.54% Upside)
Technical Analysis
Options Prices
Currently, No data available
---